Samsung Biologics snatches record deal with AZ to overachieve last year's orders

Pulse 입력 2022. 8. 12. 14:21
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Source: Samsung Biologics Co.]
Samsung Biologics has upsized its contract manufacturing deal with AstraZeneca to 457 billion won ($350 million), the single largest order to help the world’s largest contract development and manufacturing organization (CDMO) in terms of capacity overachieve last year’s order book.

Samsung Biologics said in a regulatory filing on Friday it has signed a letter of intent for contract renewal worth $350 million with the British pharma giant. What product will be manufactured was not disclosed under a mutual agreement.

The new deal is an extension to an initial contract signed in May last year. The contract was not publicized as the value did not meet the disclosure requirements. The fresh deal represents nearly 30 percent of Samsung Biologics’ revenue 1.56 trillion won last year.

The order is the largest ever for Samsung Biologics in Korean currency. The previous record was a $368 million deal signed with GSK in August 2020, which was equivalent to about 439 billion won at the time.

Samsung Biologics has so far won eight CMO deals with seven multinational pharmaceutical companies this year. The accumulated deal value comes to 1.27 trillion won, already exceeding last year’s total of 1.16 trillion won.

Shares of Samsung Biologics were 0.2 percent higher at 906,000 won.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지

이 기사에 대해 어떻게 생각하시나요?